APA (7th ed.) Citation

Lieverse, R. I. Y., Van Limbergen, E. J., Oberije, C. J. G., Troost, E. G. C., Hadrup, S. R., Dingemans, A. C., . . . Lambin, P. (2020). Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled open-label phase II trial. BMC cancer, 20, . https://doi.org/10.1186/s12885-020-07055-1

Chicago Style (17th ed.) Citation

Lieverse, Relinde I. Y., et al. "Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) Versus Standard of Care in Stage IV NSCLC Patients, ImmunoSABR: A Multicentre, Randomised Controlled Open-label Phase II Trial." BMC Cancer 20 (2020). https://doi.org/10.1186/s12885-020-07055-1.

MLA (9th ed.) Citation

Lieverse, Relinde I. Y., et al. "Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) Versus Standard of Care in Stage IV NSCLC Patients, ImmunoSABR: A Multicentre, Randomised Controlled Open-label Phase II Trial." BMC Cancer, vol. 20, 2020, https://doi.org/10.1186/s12885-020-07055-1.